PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33428109-9	2021	The mTOR inhibitor rapamycin mitigated TGF-beta-induced expression of p21, p16, and DNA damage foci and improved replicative potential of preadipocytes, supporting the cell-specific response to this cytokine.	Sirolimus	19-28	transforming growth factor alpha	Homo sapiens	39-47	
33614662-7	2021	Rapamycin mitigated these effects by activation of the classical TGF-beta/Smad signaling pathway and increasing the transcriptional activity of MAPK/AP-1.	Sirolimus	0-9	transforming growth factor alpha	Homo sapiens	65-73	
32736702-3	2020	In the present study, using cultured ARPE-19 cells, we determined that TGF-beta initiates a signaling pathway through extracellular signal-regulated kinase (ERK)-mammalian target of rapamycin complex 1 (mTORC1) that stimulates trans-differentiation and fibrosis of retinal pigment epithelium.	Sirolimus	182-191	transforming growth factor alpha	Homo sapiens	71-79	
8980296-6	1997	TGF-alpha stimulation of S6 kinase activity was inhibited in a concentration-dependent manner by rapamycin (IC50 < 0.2 nM) and the specific EGF receptor antagonist PD153035 (IC50 = 20 nM).	Sirolimus	97-106	transforming growth factor alpha	Homo sapiens	0-9	
34563639-2	2021	In the presence of TGFbeta, rapamycin induces G1 cell cycle arrest; however, in the absence of TGFbeta, cells do not arrest in G1 and progress into S-phase where rapamycin is cytotoxic rather than cytostatic.	Sirolimus	28-37	transforming growth factor alpha	Homo sapiens	19-26	
30864227-12	2019	The combination of HMGB1 short interference (si) RNA and the autophagy activator rapamycin protected against podocyte apoptosis and EMT progression by inhibiting the AKT/mTOR and TGF-beta/smad signaling pathway, respectively.	Sirolimus	81-90	transforming growth factor alpha	Homo sapiens	179-187	
17202813-5	2007	The HGF- or TGFalpha-induced increase in DNA synthesis and in albumin or fibrinogen concentrations was suppressed by the addition of rapamycin, as well as wortmannin, a phosphatidylinositol-3 kinase inhibitor.	Sirolimus	133-142	transforming growth factor alpha	Homo sapiens	12-20	
34236783-12	2022	However, rapamycin or paclitaxel concentrations >=1 mug/mL could significantly reduce the levels of anti-inflammatory cytokines IL-35 and transforming growth factor beta (TGF-beta) (P<0.05 or P<0.01), which decreased with the increase of drug concentration.	Sirolimus	9-18	transforming growth factor alpha	Homo sapiens	171-179	
34236783-14	2022	However, rapamycin or paclitaxel combined with anti- IL-10 or anti-TGF-beta can significantly enhance foam cell proliferation (P<0.01).	Sirolimus	9-18	transforming growth factor alpha	Homo sapiens	67-75